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Better understanding of the pathways regulating proliferation and metastasis of cancer cells has led to the development of novel
molecular-targeted therapies. The number of molecular-targeted agents approved for use in the clinic is growing, with many more in
clinical trials. Most of these compounds can be broadly classified into two main categories: monoclonal antibodies and small-molecule
tyrosine kinase inhibitors. The pathological processes targeted include vascular endothelial growth factor-dependent tumour
angiogenesis and epidermal growth factor receptor-dependent tumour cell proliferation and survival. Unlike conventional
chemotherapy, molecular-targeted agents offer the potential advantages of a relatively high therapeutic window and use in
combination with other anticancer strategies without overlapping toxicity. It is hoped that these drugs will become valuable
therapeutic tools within the multimodal approach to treating cancer. Recent progress in targeted antitumour therapy is discussed,
with a focus on antiangiogenesis.
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Front-line therapy for cancer not accessible to surgical interven-
tion has for the last 30 years remained a combination of chemo-
and radiotherapy. Despite recent advances in patient survival
resulting from the development of newer generation cytotoxic
agents such as the taxanes and gemcitabine, the overall prognosis
for patients with most common cancers remains poor. Failure to
improve conventional cytotoxic therapy over a period of several
decades has led cancer researchers to search for completely novel
approaches to treat cancer.
The present time is an exciting one for those involved in cancer
research and treatment, as several of the strategies embarked upon
a decade ago to enable targeting of tumour therapy are now
achieving fruition (Green, 2004). Such approaches have evolved
from a greater understanding of the pathways regulating cell
proliferation and metastasis. These studies have identified novel
cancer targets and enabled the subsequent development of targeted
therapeutics. The number of new agents approved for use in the
clinic is growing, as are the number of anticancer clinical trials. Of
more significance is that the vast majority of the anticancer clinical
trials now in progress involve novel drugs such as angiogenesis
inhibitors (nearly one half) rather than chemically modified
conventional cytotoxic agents. It is hoped that these novel agents
will become valuable therapeutic tools used in combination with
certain conventional cytotoxic agents within a multimodal
approach to the treatment of cancer. It is anticipated that such
treatments will lead to significant improvements in cancer therapy.
LIMITATIONS OF CONVENTIONAL THERAPY
As noted in the introduction, the mainstay of cancer chemotherapy
in recent decades has been the use of cytotoxic agents. In effect,
one attempts to identify an agent that kills tumour in preference to
normal cells. Despite expenditure of vast effort on the development
of cytotoxic agents, progress in recent years has been slow. In
particular, the narrow therapeutic index of cytotoxic drugs and
the emergence of drug resistance mean an unfavourable prognosis
for many cancer patients.
ANGIOGENESIS AND TUMOUR DEVELOPMENT
The majority of human cancers arise from epithelial tissues in
which the epithelial cells are undergoing continuous replication to
maintain the protective layer of cells in contact with the
environment. Examples include the lining of the lung and digestive
tract and in the epithelium of secretory organs such as the breast
and prostate. The malignant transformation of normal human
epithelial cells into carcinoma cancer cells is a complex, multistep
process. An essential change required for the development of all
cancers is mutation in appropriate genes. There are usually several
genetic changes involving, for example, proto-oncogenes, tumour-
suppressor genes and genes that regulate cell cycle events. Once a
cell has lost normal control of its growth and division, it expands
and multiplies to form the initial primary tumour. At this stage,
the tumour is fed by diffusion from nearby blood vessels; however,
as the tumour cells increase in number they eventually become
starved of nutrients such as oxygen and glucose. At this point
during the early development of a tumour, the angiogenic switch
occurs, and this is of particular relevance to therapeutic
approaches that target angiogenesis (Bergers and Benjamin,
2003). The angiogenic switch occurs when the net balance of
endogenous inhibitors and activators of angiogenesis within the
microenvironment of the developing tumour shifts in favour of
angiogenesis. While there is some evidence that this switch may
involve an irreversible change in the developing carcinoma cell
itself, it is also plausible that the cell experiences a stress response
to the lack of oxygen (hypoxia) and other nutrients within the *Correspondence: Professor R Bicknell; E-mail: bicknelr@cancer.org.uk
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normal cells will release vascular endothelial growth factor (VEGF)
and other proangiogenic factors on exposure to hypoxia. Once a
proangiogenic environment is achieved, new blood vessels grow
into the tumour, sustaining tumour growth and development. In
addition, the disorganised and immature features of the tumour
neovasculature provide readily accessible exit points for haemato-
genous spread of cancer cells, a forerunner of disseminated disease
and metastasis.
INHIBITION OF TUMOUR ANGIOGENESIS
That tumours require new vasculature to grow and that inhibition
of the growth of tumour vasculature or antiangiogenesis could
be an effective anticancer strategy has been the subject of intense
research. The idea had been around for some time, but was
popularised in the 1990s by researchers such as Judah Folkman,
who collected the evidence arguing that angiogenesis is needed
for tumour growth in a cogent article entitled ‘What is the evi-
dence that growth of solid tumours is angiogenesis dependent?’
(Folkman, 1990). An increase in angiogenesis research and several
key advances rapidly followed. For example, it became routinely
possible to culture endothelial cells in vitro, reliable and
reproducible in vivo angiogenesis assays were developed and
at the molecular level, potent peptide angiogenic factors such
as fibroblast growth factor and VEGF were identified. Two key
tenets supported early research into tumour antiangiogenesis.
Firstly, as angiogenesis is largely absent in the healthy adult, it
was widely held that an antiangiogenic approach would be
without side effects, and secondly, the fact that the endothelial
cells involved in angiogenesis are normal cells meant that they
did not suffer the genome instability seen in carcinoma cells
and as such were unlikely to develop drug resistance. Drug
resistance had long proven a problem in targeting carcinoma cells
directly.
Most deaths from cancer result from metastases and metastatic
lesions are an important target of antiangiogenic therapy.
The problem with metastases is the difficulty of treatment. Surgery
is rarely an option once the tumour has spread beyond a
limited area and the same applies to radiotherapy, hence the
attraction of systemic therapy and the sustained efforts to
develop it.
A large body of evidence has confirmed VEGF as a key regulator
of tumour angiogenesis (Ferrara et al, 2003). Vascular endothelial
growth factor is induced by both hypoxia and glucose deprivation.
It is found to a greater or lesser extent in all solid tumours and is
a potent angiogenic factor in vivo. The fact that VEGF was (until
recently) thought to be a growth factor specific for endothelium
and not widely expressed outside of tissue undergoing active
angiogenesis (tumours, wounds, tissues that form part of the
female reproductive tract) identified VEGF as a key molecular
target for antiangiogenic therapy. It is now generally accepted that
VEGF-induced angiogenesis and hyperpermeability are mediated
via binding to the VEGF receptor-2 (VEGFR-2) located on the
surface of vascular endothelial cells. Binding causes VEGFR-2
dimerisation and induces tyrosine kinase (TK)-mediated autopho-
sphorylation, which in turn leads to activation of the relevant
downstream signalling pathways.
As is frequently the case, antibodies were used initially to
obtain proof that VEGF is a valid antitumour target. Thus, in 1993
Ferrara and co-workers showed that a blocking antibody to VEGF
inhibited the growth of human tumour xenografts in athymic mice
(Kim et al, 1993). This study encouraged the development
of anti-VEGF compounds as anticancer agents, including a
humanised anti-VEGF antibody (bevacizumab [Avastint])
(Ferrara et al, 2004) as well as small-molecule inhibitors of
VEGFR-2 TK activity (Drevs et al, 2003).
KEY MOLECULAR TARGETS FOR NOVEL
ANTITUMOUR AGENTS
Although angiogenesis is an area of intense research, and both
VEGF and VEGFR-2 are key molecular targets, there are several
other molecules not involved in angiogenesis that possess suitable
characteristics for targeting by novel antitumour agents. These
include the epidermal growth factor receptor (EGFR [HER-1]) and
the related receptor HER-2, Bcr-Abl, c-Kit, platelet-derived growth
factor receptor (PDGFR) and CD20. Most of the molecular-targeted
agents currently approved or undergoing clinical evaluation can be
broadly classified into two main categories: monoclonal antibodies
or small molecule TK inhibitors (Table 1). Monoclonal antibody
therapy neutralises the ligands or receptors that are overexpressed
in particular cancers (Harris, 2004). Various transmembrane
receptors with intrinsic TK activity have been identified as
regulators of tumour or tumour vessel growth (Drevs et al,
2003). The ‘target’ for TK inhibitors is the ATP-binding site within
the kinase domain of these receptors.
Molecular-targeted agents offer a spectrum of selectivity, from
single-target monoclonal antibodies such as bevacizumab (Ferrara
et al, 2004) to a TK inhibitor such as vatalanib, which may inhibit
several targets (Wood et al, 2000). The selectivity profile of targeted
agents is a two-edged sword. A single-target drug may
be expected to have a better tolerability profile, thus increasing
the likelihood for its use in combination. However, a precise
mechanism of action means that the efficacy of single-target agents
is more susceptible to the development of tumour resistance/
redundancy. A more robust option for long-term treatment may be
either a single molecule that ‘targets’ more than one pathway or a
tailored combination of single-target drugs. An example of the
former is ZD6474, which can inhibit two key pathways in tumour
growth: VEGFR-dependent tumour angiogenesis and EGFR-depen-
dent tumour cell proliferation and survival (Wedge et al, 2002).
Unlike conventional chemotherapy, targeted agents offer the
potential advantages of a relatively high therapeutic window and
use in combination with other anticancer strategies (chemo-
therapy, radiotherapy and other targeted agents) without sig-
nificant overlapping toxicity.
TRANSLATING THE PROMISE OF TARGETED
THERAPY INTO CLINICAL BENEFIT
Ongoing use of approved agents, as well as further evaluation of
new drugs, will reveal to what extent the clinical promise of
targeted therapy is to be fulfilled. Most recently, the success with
bevacizumab in advanced metastatic colorectal cancer was an
Table 1 Monoclonal antibodies and tyrosine kinase inhibitors currently
licensed for the treatment of cancer
Drug
Molecular
target(s) Indication
Monoclonal antibodies
Bevacizumab (Avastint) VEGF Colorectal cancer
Cetuximab (Erbituxt) EGFR (HER-1) Colorectal cancer
Trastuzumab (Herceptin
s) HER-2 Breast cancer
Rituximab (Rituxan
s) CD20 B-cell non-Hodgkin’s lymphoma
Tyrosine kinase inhibitors
Erlotinib (Tarcevat) EGFR Non-small-cell lung cancer
Gefitinib (Iressat) EGFR Non-small-cell lung cancer
Imatinib (Glivec
s) Bcr-Abl
PDGFR
c-Kit
Chronic myeloid leukaemia
Gastrointestinal stromal
tumours
‘Iressa’ is a trademark of the AstraZeneca group of companies
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approach. Administration of bevacizumab with irinotecan, fluoro-
uracil and leucovorin (IFL) gave a median survival of 20.3 months
against 15.6 months for patients receiving IFL alone (Hurwitz et al,
2004). This result was a highly significant development not only in
validating the VEGF signalling axis as a clinically valuable target in
cancer therapy, but also in demonstrating that the clinical promise
of targeted therapy can be translated into meaningful benefits for
patients. Further results from clinical trials of bevacizumab and
other molecular-targeted agents in earlier cancers are eagerly
awaited. It could be that the optimal use of these agents will be
in combination with other anticancer strategies, including other
targeted therapies. For example, bevacizumab has shown its most
dramatic clinical activity in combination with cytotoxic therapy,
but is much less effective when administered alone (Hurwitz et al,
2004). This has led some to postulate that bevacizumab is effective
not only in inhibiting tumour angiogenesis but also by enabling
‘normalisation’ of tumour vessels by removing excess VEGF
produced by the tumour. Normalisation of tumour blood vessels by
antiangiogenic agents may permit an increase in blood flow and
consequently more efficient delivery of the cytotoxic agents to the
tumour cells (Ellis, 2004; Jain, 2005). Clearly, much remains to be
learned not only in terms of how antiangiogenic therapy exerts its
antitumour properties but also in the design of optimal treatment
schedules.
CONCLUSIONS AND CONSIDERATIONS
Impressive as the clinical results with bevacizumab are it is starkly
apparent that at best it inhibits but does not halt tumour growth,
so there remains much to do. Why is the therapy not affecting
more long-term survivors or even cures? The reasons are no doubt
complex. One possibility is that VEGF is not the sole angiogenic
factor produced by the tumour. Indeed, many publications have
shown that most tumours express multiple angiogenic factors
(Carmeliet and Jain, 2000; Kerbel and Folkman, 2002). Different
stresses occurring in the tumour can induce (sometimes different)
angiogenic factors. For example, hypoxia induces predominantly
VEGF (Shweiki et al, 1992) whereas oxidative stress induces both
VEGF and the strongly angiogenic interleukin-8 (Marjon et al,
2004). We have recently used a rat orthotopic xenograft bladder
cancer model to show that while a blocking VEGF antibody
reduced tumour take by 50%, tumour formation was abolished by
concomitant administration in the drinking water of the oxidative
stress blocker N-acetylcysteine (‘Parvolex’) (Brown et al, 2005).
A complementary anticancer strategy that also targets the
endothelium is tumour vascular targeting (Neri and Bicknell,
2005). Destruction of the tumour vasculature, as opposed to the
inhibition of new vessel growth, is an established idea that has
recently attracted considerable renewed interest. The two ap-
proaches may be useful in combination, for example, destroy the
tumour vasculature using a vascular targeting agent to elicit
tumour collapse and then inhibit regrowth by long-term admin-
istration of an antiangiogenic agent.
The ultimate success of any targeted agent will be measured by
whether or not it provides clinical benefit to patients. In this
respect, the current design of clinical trials involving antiangio-
genic agents may be improved by the development of rapid and
effective biomarkers to establish drug dosage and monitor clinical
response. Miller et al (2005) have recently reviewed the potential
and limitations of a wide range of techniques used for imaging
of tumour vasculature including positron emission tomography,
X-ray computed tomography, magnetic resonance imaging, ultra-
sound and optical imaging. They also discussed which methods are
likely to have the sensitivity and robustness for monitoring
responses to cancer therapy and described ways in which imaging
has been used in clinical trials to date. Such techniques will be
important additional tools for assessing the clinical efficacy of the
new drugs being developed.
The clinical utility of targeted agents is now established for both
tumour and tumour blood vessel targets, with a number of agents
already approved (Table 1) and others at various stages of clinical
development. Nevertheless, challenges remain and several aspects
of targeted therapy need to be optimised. These include treatment
schedules and use in combination with certain conventional
anticancer strategies or other targeted agents, as well as
identification of those patients, disease settings and tumour types
most likely to respond.
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